Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. director Steven W. Lefkowitz reported receiving 30,453 shares of common stock on January 26, 2026 as restricted stock units granted at $0.00 per share. These units each represent one share of common stock and will vest in full on January 26, 2027, subject to his continued service.
After this grant, he beneficially owns 125,951 shares directly. He also has indirect beneficial ownership of 30,152 shares through the Wade Capital Corporation Money Purchase Plan, where he has voting and investment control, and 2,000 shares held by his spouse.
CorMedix Inc. director Alan W. Dunton received an equity award in the form of restricted stock units. On January 26, 2026, he was granted 30,453 restricted stock units of CorMedix common stock at a grant price of $0.00 per unit, increasing his beneficial ownership to 70,703 shares.
Each restricted stock unit represents the right to receive one share of common stock. The units will vest in full on January 26, 2027, provided he continues serving the company through the vesting date.
CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share. Following this grant, he beneficially owns 66,453 CorMedix shares directly.
The award consists of restricted stock units issued on January 26, 2026. Each unit converts into one share of common stock and will vest in full on January 26, 2027, provided he continues to serve through the vesting date.
CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting an equity compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of CorMedix common stock. The RSUs will vest in full on January 26, 2027, provided Scott continues his service through the vesting date. After this grant, he beneficially owns 68,786 shares of CorMedix common stock in direct ownership form.
CorMedix Inc. director Janet Dillione reported a sale of company stock. On January 21, 2026, she sold 10,000 shares of CorMedix common stock at a weighted average price of $6.88 per share, in multiple trades executed between $6.85 and $6.90 per share. After this transaction, she beneficially owned 38,473 shares of CorMedix common stock directly.
The filing notes that the reported price is an average across several individual trades, and the director has agreed to provide detailed trade and pricing information to regulators, the company, or any security holder who requests it.
A person associated with CRMD has filed a notice to sell common stock under Rule 144. The filing shows a planned sale of 10,000 common shares through Merrill Lynch, with an aggregate market value of 68,502, on or about 01/21/2026 on the NASDAQ. The issuer had 78,789,045 shares of common stock outstanding. The seller acquired these 10,000 shares on 01/17/2026 via stock plan activity.
Over the prior three months, the same seller completed additional sales of common stock, including 34,000 shares for 407,030 on 12/09/2025, 46,657 shares for 465,169 on 12/02/2025, and 26,343 shares for 260,805 on 11/24/2025. This Form 144 is a notice of intent and does not by itself confirm that the planned shares have been sold.
CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported a Form 4 insider transaction involving company common stock. On 01/12/2026, a transaction coded "F" was reported for 5,794 shares of common stock at a price of $7.15 per share. Following this transaction, she directly beneficially owned 160,301 shares of CorMedix common stock. The filing notes that the transaction is being reported late due to an inadvertent administrative error.
CorMedix Inc. Chief Executive Officer Joseph Todisco, who also serves as a director, reported equity award-related transactions in the company’s common stock. On 01/16/2026, he exercised a stock option for 29,585 shares of common stock at an exercise price of $3.38 per share from an option originally granted on 5/10/2022, increasing his directly held common stock to 521,664 shares and leaving 411,245 options outstanding. The filing also reports transactions coded “F” on 01/12/2026 for 17,417 shares at $7.15 and on 01/17/2026 for 22,665 shares at $6.78, after which he directly held 492,079 and then 498,999 common shares. A footnote explains that the option exercise price was paid in cash and that no sales of stock were made. Another footnote states the Form 4 is being reported late due to an inadvertent administrative error.
CorMedix Inc.’s Chief Commercial Officer, Michael David Seckler, reported an equity compensation grant of 133,156 shares of common stock on 01/08/2026. The filing shows these as restricted stock units, each representing the right to receive one share of CorMedix common stock at a stated price of $0 per unit.
The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, and vesting requires Mr. Seckler to remain employed through each applicable vesting date. After this grant, he beneficially owns 133,156 shares directly.
CorMedix Inc. filed an initial ownership report for executive Michael David Seckler, its Chief Commercial Officer, showing no beneficial ownership of company securities. This Form 3 states that no non-derivative or derivative securities are beneficially owned at the time of the report. The filing is signed by an attorney-in-fact under a power of attorney, which authorizes them to sign on the officer’s behalf.